UA82479C2 - Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) - Google Patents
Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) Download PDFInfo
- Publication number
- UA82479C2 UA82479C2 UA20041109409A UA20041109409A UA82479C2 UA 82479 C2 UA82479 C2 UA 82479C2 UA 20041109409 A UA20041109409 A UA 20041109409A UA 20041109409 A UA20041109409 A UA 20041109409A UA 82479 C2 UA82479 C2 UA 82479C2
- Authority
- UA
- Ukraine
- Prior art keywords
- mma
- nucleotides
- sequence
- dna sequence
- genome
- Prior art date
Links
- 238000003780 insertion Methods 0.000 title claims abstract description 106
- 230000037431 insertion Effects 0.000 title claims abstract description 106
- 241000700605 Viruses Species 0.000 title claims abstract description 88
- 206010046865 Vaccinia virus infection Diseases 0.000 title abstract 2
- 208000007089 vaccinia Diseases 0.000 title abstract 2
- 239000013600 plasmid vector Substances 0.000 claims abstract description 27
- 229960005486 vaccine Drugs 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 67
- 239000002773 nucleotide Substances 0.000 claims description 65
- 125000003729 nucleotide group Chemical group 0.000 claims description 63
- 239000012634 fragment Substances 0.000 claims description 36
- 206010037660 Pyrexia Diseases 0.000 claims description 30
- 108091026890 Coding region Proteins 0.000 claims description 20
- 108020004414 DNA Proteins 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 14
- 238000010367 cloning Methods 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 230000006801 homologous recombination Effects 0.000 claims description 11
- 238000002744 homologous recombination Methods 0.000 claims description 11
- 241000700618 Vaccinia virus Species 0.000 claims description 10
- 238000001890 transfection Methods 0.000 claims description 10
- 108091029795 Intergenic region Proteins 0.000 claims description 9
- 238000000746 purification Methods 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 7
- 230000000890 antigenic effect Effects 0.000 claims description 7
- 108091007433 antigens Proteins 0.000 claims description 7
- 102000036639 antigens Human genes 0.000 claims description 7
- 238000012015 optical character recognition Methods 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 108700026244 Open Reading Frames Proteins 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 206010061598 Immunodeficiency Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000007813 immunodeficiency Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 241000710842 Japanese encephalitis virus Species 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 101150048805 okr gene Proteins 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 108091029865 Exogenous DNA Proteins 0.000 abstract description 30
- 230000010354 integration Effects 0.000 abstract description 3
- 101800003332 Metamorphosin A Proteins 0.000 description 139
- 239000013598 vector Substances 0.000 description 64
- 210000004027 cell Anatomy 0.000 description 55
- 230000003321 amplification Effects 0.000 description 16
- 238000003199 nucleic acid amplification method Methods 0.000 description 16
- 238000012217 deletion Methods 0.000 description 15
- 230000037430 deletion Effects 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 14
- 108091081024 Start codon Proteins 0.000 description 13
- 239000003550 marker Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000003252 repetitive effect Effects 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 8
- 108700008625 Reporter Genes Proteins 0.000 description 8
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 6
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 5
- 101100237844 Mus musculus Mmp19 gene Proteins 0.000 description 5
- 238000010222 PCR analysis Methods 0.000 description 5
- 229960000723 ampicillin Drugs 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 210000001161 mammalian embryo Anatomy 0.000 description 4
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 4
- 229960000951 mycophenolic acid Drugs 0.000 description 4
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012409 standard PCR amplification Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 229940075420 xanthine Drugs 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 241000725619 Dengue virus Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000212695 Zesius Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 108091005948 blue fluorescent proteins Proteins 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- DOSMHBDKKKMIEF-UHFFFAOYSA-N 2-[3-(diethylamino)-6-diethylazaniumylidenexanthen-9-yl]-5-[3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propylsulfamoyl]benzenesulfonate Chemical compound C1=CC(=[N+](CC)CC)C=C2OC3=CC(N(CC)CC)=CC=C3C(C=3C(=CC(=CC=3)S(=O)(=O)NCCCN3C4=CC=CC=C4C(C=4C(NC(=O)C=4C=4C5=CC=CC=C5N(C)C=4)=O)=C3)S([O-])(=O)=O)=C21 DOSMHBDKKKMIEF-UHFFFAOYSA-N 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001074528 Homo sapiens Regulating synaptic membrane exocytosis protein 1 Proteins 0.000 description 2
- 102000008100 Human Serum Albumin Human genes 0.000 description 2
- 108091006905 Human Serum Albumin Proteins 0.000 description 2
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 2
- 102100036240 Regulating synaptic membrane exocytosis protein 1 Human genes 0.000 description 2
- 101100468538 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RGM1 gene Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000013902 inosinic acid Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000006825 purine synthesis Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000017613 viral reproduction Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000391729 Botia Species 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 241000700626 Cowpox virus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102220563749 Cysteine and histidine-rich protein 1_A42K_mutation Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100291267 Drosophila melanogaster Miga gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101001074548 Homo sapiens Regulating synaptic membrane exocytosis protein 2 Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100031955 Lon protease homolog, mitochondrial Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100187130 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nim-1 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 102100036266 Regulating synaptic membrane exocytosis protein 2 Human genes 0.000 description 1
- 108700029229 Transcriptional Regulatory Elements Proteins 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 101150082998 pi gene Proteins 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940024231 poxvirus vaccine Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940124551 recombinant vaccine Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000006648 viral gene expression Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200752 | 2002-05-16 | ||
| DKPA200200753 | 2002-05-16 | ||
| US10/514,761 US7550147B2 (en) | 2002-05-16 | 2003-05-14 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) |
| PCT/EP2003/005045 WO2003097845A1 (en) | 2002-05-16 | 2003-05-14 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva) |
| US12/468,127 US8034354B2 (en) | 2002-05-16 | 2009-05-19 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) |
| US13/234,230 US8435543B2 (en) | 2002-05-16 | 2011-09-16 | Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (MVA) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA82479C2 true UA82479C2 (uk) | 2008-04-25 |
Family
ID=29551228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041109409A UA82479C2 (uk) | 2002-05-16 | 2003-05-14 | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
Country Status (22)
| Country | Link |
|---|---|
| US (14) | US7550147B2 (enExample) |
| EP (3) | EP2253709B1 (enExample) |
| JP (4) | JP4895505B2 (enExample) |
| KR (4) | KR101041691B1 (enExample) |
| CN (6) | CN1653183B (enExample) |
| AT (1) | ATE315660T1 (enExample) |
| AU (4) | AU2003236646B2 (enExample) |
| BR (2) | BRPI0311178B8 (enExample) |
| CA (3) | CA2481799C (enExample) |
| DE (1) | DE60303218T2 (enExample) |
| DK (2) | DK1506301T3 (enExample) |
| EA (3) | EA007811B1 (enExample) |
| ES (1) | ES2256776T3 (enExample) |
| IL (4) | IL164177A0 (enExample) |
| MX (2) | MXPA04010713A (enExample) |
| NO (3) | NO334273B1 (enExample) |
| NZ (2) | NZ536502A (enExample) |
| PL (2) | PL218318B1 (enExample) |
| PT (1) | PT1407033E (enExample) |
| SI (1) | SI1407033T1 (enExample) |
| UA (1) | UA82479C2 (enExample) |
| WO (2) | WO2003097845A1 (enExample) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4101327C1 (enExample) * | 1991-01-18 | 1991-10-24 | Mercedes-Benz Aktiengesellschaft, 7000 Stuttgart, De | |
| HU230198B1 (hu) * | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| EP1420822B2 (en) * | 2002-04-19 | 2017-07-05 | Bavarian Nordic A/S | Modified vaccinia virus ankara for the vaccination of neonates |
| US7501127B2 (en) * | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| AU2003264144C1 (en) * | 2002-09-05 | 2009-12-17 | Bavarian Nordic A/S | Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions |
| JP5052893B2 (ja) * | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
| GB2402391A (en) * | 2003-06-04 | 2004-12-08 | Oxxon Pharmaccines Ltd | Fowlpox recombinant genome |
| US7951576B2 (en) * | 2004-11-05 | 2011-05-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for preparing cells and viruses |
| CN101128217B (zh) * | 2005-02-23 | 2012-04-25 | 巴法里安诺迪克有限公司 | 改良的痘病毒快速诱导抗痘病毒或其它传染物的免疫力的用途 |
| CA2651456A1 (en) * | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Recombinant vectors |
| DK2402451T3 (en) * | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
| EP2415783B1 (en) | 2006-10-16 | 2016-12-14 | Genelux Corporation | Modified vaccinia virus strains for use in a diagnostic and therapeutic method |
| US8440202B2 (en) * | 2006-11-09 | 2013-05-14 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using the prime-boost approach |
| WO2008127307A2 (en) * | 2006-11-09 | 2008-10-23 | The United States Of America As Represented By The Secretary Of The Navy | Induction of an immune response against dengue virus using prime-boost approach |
| CL2008000249A1 (es) * | 2007-01-30 | 2008-05-30 | Transgene Sa | Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus |
| US8268327B2 (en) | 2007-04-27 | 2012-09-18 | Bavarian Nordic A/S | Immediate protection against pathogens via MVA |
| KR101514473B1 (ko) * | 2007-05-15 | 2015-04-22 | 트랜스진 에스.에이. | 다중 유전자 발현용 벡터 |
| EP2155883A1 (en) * | 2007-05-30 | 2010-02-24 | Wyeth LLC | Raccoon poxvirus expressing genes of feline antigens |
| TW200907058A (en) * | 2007-05-30 | 2009-02-16 | Wyeth Corp | Raccoon poxvirus expressing rabies glycoproteins |
| ES2608604T3 (es) | 2007-10-18 | 2017-04-12 | Bavarian Nordic A/S | Uso de MVA para tratar el cáncer de próstata |
| US20110052627A1 (en) * | 2008-06-20 | 2011-03-03 | Paul Chaplin | Recombinant modified vaccinia virus measles vaccine |
| KR100894430B1 (ko) * | 2008-11-11 | 2009-04-22 | 시스템디엔디(주) | 초음파, 음향 및 온도변화를 이용한 밸브의 유체누설 측정장치 및 이를 이용한 유체누설 측정방법 |
| EP2352834B1 (en) * | 2008-11-21 | 2016-12-21 | Bavarian Nordic A/S | Vector comprising multiple homologous nucleotide sequences |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| JP2013507107A (ja) | 2009-10-08 | 2013-03-04 | バヴァリアン・ノルディック・アクティーゼルスカブ | Ｈｉｖに対するヒトにおける広範なｔ細胞応答の生成 |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| WO2011087839A1 (en) | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
| CN103118709A (zh) * | 2010-03-26 | 2013-05-22 | 新兴产品开发盖瑟斯堡有限公司 | 流感病毒基质2蛋白的胞外域、其表达系统和应用 |
| CA2802430C (en) | 2010-07-20 | 2021-07-20 | Bavarian Nordic A/S | Method for harvesting poxvirus |
| AU2011305348A1 (en) * | 2010-09-23 | 2013-04-18 | Baxter Healthcare Sa | Recombinant viral vectors and methods for inducing an immune response to yellow fever virus |
| US9173933B2 (en) | 2010-10-15 | 2015-11-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara influenza vaccine |
| EP2697368B1 (en) | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| WO2013083254A1 (en) | 2011-12-09 | 2013-06-13 | Bavarian Nordic A/S | Poxvirus vector for the expression of bacterial antigens linked to tetanus toxin fragment c |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| HK1203358A1 (en) | 2012-06-05 | 2015-10-30 | The Australian National University | Vaccination with interleukin-4 antagonists |
| SI2879702T1 (sl) | 2012-08-01 | 2020-02-28 | Bavarian Nordic A/S | Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV) |
| WO2014043535A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Compositions for the treatment of cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| EP2908851A1 (en) | 2012-10-19 | 2015-08-26 | Bavarian Nordic Inc. | Methods and compositions for the treatment of cancer |
| EP2968528B1 (en) * | 2013-03-15 | 2022-02-23 | Sementis Limited | Immune modulation |
| DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
| WO2014139587A1 (en) * | 2013-03-15 | 2014-09-18 | Okairòs Ag | Improved poxviral vaccines |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| KR101623498B1 (ko) | 2014-10-16 | 2016-05-24 | 대한민국 | 약독화 백시니아 바이러스주 kvac１０３ |
| KR101645642B1 (ko) | 2014-10-16 | 2016-08-11 | 대한민국 | Kvac１０３ 유래의 재조합 백시니아 바이러스 |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| KR20160140075A (ko) * | 2015-05-29 | 2016-12-07 | 코오롱생명과학 주식회사 | 폭스바이러스 유래 프로모터 및 이를 포함하는 벡터 |
| US11103570B2 (en) * | 2015-06-15 | 2021-08-31 | Bavarian Nordic A/S | Recombinant modified vaccinia virus Ankara (MVA) foot and mouth disease virus (FMDV) vaccine |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN106591361A (zh) * | 2015-10-20 | 2017-04-26 | 钱文斌 | 一种重组痘溶瘤病毒及其构建方法和应用 |
| CN109071592B (zh) | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
| WO2017129765A1 (en) | 2016-01-29 | 2017-08-03 | Bavarian Nordic A/S | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |
| US20190030157A1 (en) * | 2016-02-03 | 2019-01-31 | Geovax Inc. | Compositions and Methods for Generating an Immune Response to a Flavivirus |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3452087A1 (en) | 2016-05-02 | 2019-03-13 | Janssen Vaccines & Prevention B.V. | Therapeutic hpv vaccine combinations |
| MY200887A (en) * | 2016-08-19 | 2024-01-22 | Sementis Ltd | Viral Vaccines |
| EP3518656A4 (en) * | 2016-09-30 | 2020-09-30 | Monsanto Technology LLC | PROCESS FOR SELECTING TARGET SITES FOR MODIFICATION OF SITE-SPECIFIC GENOME IN PLANTS |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| BR112019026126A2 (pt) * | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| WO2019217922A1 (en) | 2018-05-11 | 2019-11-14 | City Of Hope | Genetically modified recombinant vaccinia ankara (rmva) vaccines of improved stability and methods of preparation thereof |
| CN112512569A (zh) * | 2018-05-11 | 2021-03-16 | 希望之城 | 表达多个巨细胞病毒(cmv)抗原的mva载体及其用途 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN113924114A (zh) | 2019-05-22 | 2022-01-11 | 吉利德科学公司 | Tlr7调节化合物和hiv疫苗的组合 |
| CN111979204B (zh) * | 2019-05-24 | 2023-10-13 | 杭州功楚生物科技有限公司 | 携带海绵凝集素基因的溶瘤痘苗病毒、构建方法及用途 |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| EP3842065A1 (en) * | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| TW202203966A (zh) * | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗 |
| BR112023015467A2 (pt) | 2021-02-02 | 2023-10-10 | Geovax Inc | Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica |
| EP4551240A1 (en) | 2022-07-08 | 2025-05-14 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
| FR3171450A1 (fr) | 2025-01-17 | 2026-07-24 | Odimma Therapeutics | Virus enveloppé pour la transfection d’acides nucléiques exogènes. |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5338683A (en) * | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
| JPH0795956B2 (ja) * | 1986-09-22 | 1995-10-18 | 京都大学長 | ポックスウイルス由来発現制御領域 |
| US5093258A (en) * | 1988-08-26 | 1992-03-03 | Therion Biologics Corporation | Recombinant fowlpox virus and recombination vector |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5651972A (en) | 1989-04-21 | 1997-07-29 | University Of Florida Research Foundation, Inc. | Use of recombinant swine poxvirus as a live vaccine vector |
| MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
| US5514375A (en) | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
| US6893845B1 (en) * | 1990-09-28 | 2005-05-17 | Applied Molecular Evolution, Inc. | Surface expression libraries of heteromeric receptors |
| EP0575491B1 (en) * | 1991-03-07 | 2003-08-13 | Virogenetics Corporation | Genetically engineered vaccine strain |
| BE1004877A3 (fr) * | 1991-05-27 | 1993-02-16 | Solvay | Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus. |
| FR2679249B1 (fr) * | 1991-07-15 | 1993-11-26 | Centre Nal Recherc Scientifique | Souches de levure avec integration stable de genes heterologues. |
| CA2110505A1 (en) | 1991-07-26 | 1993-02-18 | Enzo Paoletti | Infectious bursal disease virus recombinant poxvirus vaccine |
| EP1380651A2 (en) * | 1991-08-26 | 2004-01-14 | Baxter Healthcare S.A. | Recombinant fowlpox virus with intact FPV-tk-gene |
| ATE181108T1 (de) * | 1991-08-26 | 1999-06-15 | Immuno Ag | Direkt molekuläre klonierung eines modifizierten genoms eines chordopocken-virus |
| US5676950A (en) | 1994-10-28 | 1997-10-14 | University Of Florida | Enterically administered recombinant poxvirus vaccines |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| EP0753581A1 (en) * | 1995-07-10 | 1997-01-15 | Immuno Ag | Improved recombinant eukaryotic cytoplasmic viruses, method for their production and their use as vaccines |
| DE19629828A1 (de) * | 1996-07-24 | 1998-01-29 | Bayer Ag | Carbanilide |
| ID19548A (id) * | 1996-09-24 | 1998-07-23 | Bavarian Nordic Res Inst As | Virus mva rekombinan yang mengekspresikan antigen-antigen virus demam dan penggunaan daripadanya dalam vaksin-vaksin |
| AUPP380598A0 (en) * | 1998-05-29 | 1998-06-25 | Commonwealth Scientific And Industrial Research Organisation | Genetically manipulated entomopoxvirus |
| US6252871B1 (en) | 1998-07-01 | 2001-06-26 | Powerwave Technologies, Inc. | Switchable combiner/splitter |
| US20040265324A1 (en) * | 1999-03-23 | 2004-12-30 | Cardosa Mary Jane | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| WO2000073476A1 (en) * | 1999-05-28 | 2000-12-07 | Gsf Forschungszentrum Für Umwelt Und Gesundheit Gmbh | Vector for integration of heterologous sequences into poxviral genomes |
| KR100880765B1 (ko) * | 2000-03-14 | 2009-02-02 | 버베리안 노딕 에이/에스 | 변형된 백시니아 바이러스 안카라(ｍｖａ)의 변형 균주 |
| CA2341356C (en) * | 2000-04-14 | 2011-10-11 | Transgene S.A. | Poxvirus with targeted infection specificity |
| EP1326990B1 (en) * | 2000-08-29 | 2007-09-19 | Wyeth Holdings Corporation | Packaging of positive-strand rna virus replicon particles |
| HU230198B1 (hu) | 2000-11-23 | 2015-10-28 | Bavarian Nordic A/S | Módosított Vacciniavírus Ankara-variáns |
| UA82479C2 (uk) | 2002-05-16 | 2008-04-25 | Бавариан Нордика А/С | Міжгенні регіони як сайти вставки в геном модифікованого вірусу коров'ячої віспи ankara (mva) |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| ATE365220T1 (de) * | 2002-11-25 | 2007-07-15 | Bavarian Nordic As | Mindestens zwei ati promotoren enthaltendes rekombinantes pockenvirus |
-
2003
- 2003-05-14 UA UA20041109409A patent/UA82479C2/uk unknown
- 2003-05-14 CN CN038111063A patent/CN1653183B/zh not_active Expired - Lifetime
- 2003-05-14 JP JP2004506500A patent/JP4895505B2/ja not_active Expired - Lifetime
- 2003-05-14 KR KR1020047018165A patent/KR101041691B1/ko not_active Expired - Lifetime
- 2003-05-14 SI SI200330215T patent/SI1407033T1/sl unknown
- 2003-05-14 US US10/514,761 patent/US7550147B2/en not_active Expired - Lifetime
- 2003-05-14 AT AT03752741T patent/ATE315660T1/de active
- 2003-05-14 NZ NZ536502A patent/NZ536502A/en not_active IP Right Cessation
- 2003-05-14 MX MXPA04010713A patent/MXPA04010713A/es active IP Right Grant
- 2003-05-14 EA EA200401507A patent/EA007811B1/ru not_active IP Right Cessation
- 2003-05-14 DE DE2003603218 patent/DE60303218T2/de not_active Expired - Lifetime
- 2003-05-14 DK DK03735384T patent/DK1506301T3/da active
- 2003-05-14 EA EA200401506A patent/EA012160B1/ru not_active IP Right Cessation
- 2003-05-14 MX MXPA04011194A patent/MXPA04011194A/es active IP Right Grant
- 2003-05-14 EA EA200900180A patent/EA020230B1/ru not_active IP Right Cessation
- 2003-05-14 ES ES03752741T patent/ES2256776T3/es not_active Expired - Lifetime
- 2003-05-14 PL PL372088A patent/PL218318B1/pl unknown
- 2003-05-14 CN CN2012101928085A patent/CN102703393A/zh active Pending
- 2003-05-14 JP JP2004506501A patent/JP4693092B2/ja not_active Expired - Lifetime
- 2003-05-14 NZ NZ536501A patent/NZ536501A/en not_active IP Right Cessation
- 2003-05-14 BR BRPI0311178A patent/BRPI0311178B8/pt not_active IP Right Cessation
- 2003-05-14 US US10/510,189 patent/US7338662B2/en not_active Expired - Lifetime
- 2003-05-14 IL IL16417703A patent/IL164177A0/xx active IP Right Grant
- 2003-05-14 CN CN200910208520A patent/CN101831411A/zh active Pending
- 2003-05-14 CN CN2012101926963A patent/CN102719408A/zh active Pending
- 2003-05-14 KR KR1020107021891A patent/KR101138067B1/ko not_active Expired - Lifetime
- 2003-05-14 PT PT03752741T patent/PT1407033E/pt unknown
- 2003-05-14 EP EP10008120.7A patent/EP2253709B1/en not_active Expired - Lifetime
- 2003-05-14 DK DK03752741T patent/DK1407033T3/da active
- 2003-05-14 EP EP20030752741 patent/EP1407033B1/en not_active Expired - Lifetime
- 2003-05-14 AU AU2003236646A patent/AU2003236646B2/en not_active Expired
- 2003-05-14 WO PCT/EP2003/005045 patent/WO2003097845A1/en not_active Ceased
- 2003-05-14 KR KR1020117031095A patent/KR20120002627A/ko not_active Withdrawn
- 2003-05-14 CA CA2481799A patent/CA2481799C/en not_active Expired - Lifetime
- 2003-05-14 KR KR1020047018293A patent/KR101005630B1/ko not_active Expired - Lifetime
- 2003-05-14 AU AU2003242540A patent/AU2003242540A1/en not_active Abandoned
- 2003-05-14 PL PL372093A patent/PL216760B1/pl unknown
- 2003-05-14 CN CNB038111225A patent/CN100494388C/zh not_active Expired - Lifetime
- 2003-05-14 EP EP20030735384 patent/EP1506301B1/en not_active Expired - Lifetime
- 2003-05-14 CA CA 2812019 patent/CA2812019A1/en not_active Abandoned
- 2003-05-14 CN CN2011100588236A patent/CN102199628A/zh active Pending
- 2003-05-14 IL IL16417203A patent/IL164172A0/xx unknown
- 2003-05-14 CA CA2481521A patent/CA2481521C/en not_active Expired - Lifetime
- 2003-05-14 BR BR0310051A patent/BR0310051A/pt not_active IP Right Cessation
- 2003-05-14 WO PCT/EP2003/005047 patent/WO2003097846A1/en not_active Ceased
-
2004
- 2004-11-12 NO NO20044940A patent/NO334273B1/no not_active IP Right Cessation
- 2004-12-16 NO NO20045480A patent/NO336489B1/no not_active IP Right Cessation
-
2007
- 2007-11-15 US US11/985,510 patent/US9109233B2/en active Active
-
2008
- 2008-07-28 IL IL19308808A patent/IL193088A/en active IP Right Grant
- 2008-07-28 IL IL193087A patent/IL193087A/en active IP Right Grant
- 2008-12-09 AU AU2008255213A patent/AU2008255213B2/en not_active Expired
- 2008-12-19 US US12/339,743 patent/US20100173388A1/en not_active Abandoned
-
2009
- 2009-02-03 AU AU2009200380A patent/AU2009200380C1/en not_active Expired
- 2009-05-19 US US12/468,120 patent/US7964374B2/en not_active Expired - Lifetime
- 2009-05-19 US US12/468,127 patent/US8034354B2/en not_active Expired - Lifetime
-
2010
- 2010-08-05 JP JP2010176511A patent/JP2011004755A/ja active Pending
- 2010-08-05 JP JP2010176512A patent/JP5777199B2/ja not_active Expired - Lifetime
- 2010-09-30 US US12/894,589 patent/US20110053260A1/en not_active Abandoned
- 2010-09-30 US US12/894,550 patent/US20110053259A1/en not_active Abandoned
-
2011
- 2011-04-15 US US13/087,715 patent/US8288125B2/en not_active Expired - Fee Related
- 2011-04-15 US US13/087,649 patent/US8309326B2/en not_active Expired - Fee Related
- 2011-09-15 US US13/233,329 patent/US8414900B2/en not_active Expired - Fee Related
- 2011-09-16 US US13/234,230 patent/US8435543B2/en not_active Expired - Fee Related
- 2011-09-29 NO NO20111324A patent/NO20111324A1/no not_active Application Discontinuation
-
2012
- 2012-02-13 US US13/371,580 patent/US20120178157A1/en not_active Abandoned
-
2013
- 2013-05-02 US US13/886,093 patent/US8741308B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4895505B2 (ja) | 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域 | |
| KR20050083839A (ko) | 두개 이상의 우두 ａｔｉ 프로모터를 포함하는 재조합폭스바이러스 | |
| ES2256747T3 (es) | Expresion de genes en el virus de la vacuna modificado, usando el promotor ati de la viruela de la vaca. | |
| HK1171249A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1170772A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| HK1156979A (en) | Recombinant poxvirus expressing homologous genes inserted into the poxviral genome | |
| MXPA06005559A (es) | Promotores para la expresion en vaccinia virus ankara modificado |